Insider Selling: Exelixis, Inc. (NASDAQ:EXEL) VP Sells 1,000 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) VP Patrick J. Haley sold 1,000 shares of the stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $20.39, for a total transaction of $20,390.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

Patrick J. Haley also recently made the following trade(s):

  • On Tuesday, August 6th, Patrick J. Haley sold 25,000 shares of Exelixis stock. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00.
  • On Wednesday, July 10th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The stock was sold at an average price of $20.96, for a total transaction of $20,960.00.
  • On Monday, June 10th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The stock was sold at an average price of $20.23, for a total transaction of $20,230.00.

EXEL traded down $0.25 during midday trading on Wednesday, hitting $19.95. The company had a trading volume of 1,569,506 shares, compared to its average volume of 3,212,073. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.64 and a quick ratio of 8.53. The company has a market capitalization of $6.04 billion, a P/E ratio of 13.95 and a beta of 1.98. Exelixis, Inc. has a twelve month low of $13.42 and a twelve month high of $25.31. The firm has a 50-day moving average price of $20.93.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.02. The firm had revenue of $240.28 million during the quarter, compared to analysts’ expectations of $226.97 million. Exelixis had a net margin of 70.52% and a return on equity of 31.31%. The company’s quarterly revenue was up 29.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.31 EPS. On average, research analysts anticipate that Exelixis, Inc. will post 0.89 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace LLP boosted its position in shares of Exelixis by 7,709.5% in the second quarter. Marshall Wace LLP now owns 499,573 shares of the biotechnology company’s stock valued at $10,676,000 after acquiring an additional 493,176 shares during the period. Nomura Holdings Inc. bought a new position in Exelixis during the second quarter valued at approximately $698,000. Man Group plc boosted its stake in Exelixis by 194.8% during the second quarter. Man Group plc now owns 156,599 shares of the biotechnology company’s stock valued at $3,346,000 after buying an additional 103,477 shares during the last quarter. Private Advisor Group LLC bought a new position in Exelixis during the second quarter valued at approximately $288,000. Finally, Tower Research Capital LLC TRC boosted its stake in Exelixis by 187.3% during the second quarter. Tower Research Capital LLC TRC now owns 31,528 shares of the biotechnology company’s stock valued at $674,000 after buying an additional 20,555 shares during the last quarter. Hedge funds and other institutional investors own 77.17% of the company’s stock.

A number of equities research analysts recently issued reports on EXEL shares. Stifel Nicolaus increased their target price on shares of Exelixis from $22.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, August 1st. BidaskClub upgraded shares of Exelixis from a “sell” rating to a “hold” rating in a research report on Friday, July 19th. Cowen set a $25.00 target price on shares of Exelixis and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research report on Tuesday, August 6th. Finally, Morgan Stanley set a $27.00 target price on shares of Exelixis and gave the stock a “hold” rating in a research report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company’s stock. Exelixis currently has a consensus rating of “Hold” and a consensus price target of $27.75.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

See Also: How to Invest in Marijuana Stocks

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.